Published in J Med Chem on August 01, 1985
Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res (2007) 0.88
Preparation of lymphocyte-activating factor from continuous murine macrophage cell lines. Cell Immunol (1977) 2.81
Partial purification of human lymphocyte-activating factor (LAF) by ultrafiltration and electrophoretic techniques. J Immunol (1977) 2.58
Overexpression of metallothionein confers resistance to anticancer drugs. Science (1988) 2.03
Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther (1971) 1.44
A revised scheme for the evaluation of automatic instruments for use in clinical chemistry. Ann Clin Biochem (1974) 1.40
Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res (1999) 1.12
Dihydrofolate reductase from Trypanosoma equiperdum. I. Isolation, partial purification, and properties. Mol Pharmacol (1967) 1.09
A recommended scheme for the evaluation of kits in the clinical laboratory. Ann Clin Biochem (1980) 1.09
Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones. J Med Chem (1991) 1.06
Carbocyclic analogues of the potent cytidine deaminase inhibitor 1-(beta-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine). J Med Chem (1998) 1.03
Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol (1993) 1.01
Comparative properties of schistosomal and filarial dihydrofolate reductases. Biochem Pharmacol (1972) 0.98
B16 murine melanoma and aging: slower growth and longer survival in old mice. J Natl Cancer Inst (1984) 0.97
The decarbethoxylation of geminal dicarbethoxy compounds. Tetrahedron Lett (1967) 0.96
Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. Science (1985) 0.95
Synthesis of 1,3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase. J Med Chem (1980) 0.95
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem (1993) 0.94
Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem (1986) 0.92
Effect of cytotoxic monoclonal antibody depletion of T-lymphocyte subpopulations on bleomycin-induced lung damage in C57BL/6J mice. Toxicol Appl Pharmacol (1989) 0.92
Mechanisms of asbestos-induced nitric oxide production by rat alveolar macrophages in inhalation and in vitro models. Free Radic Biol Med (1998) 0.92
Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. Cancer Lett (1995) 0.91
Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice. Toxicol Appl Pharmacol (1989) 0.91
Specific in vivo and in vitro antibody response to tetanus toxoid immunization. Clin Exp Immunol (1982) 0.90
Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol (1995) 0.90
Cyclic urea nucleosides. Cytidine deaminase activity as a function of aglycon ring size. J Med Chem (1981) 0.90
Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med (1996) 0.90
Nitric oxide modulates lymphocyte proliferation but not secretion of IL-2. Immunol Invest (1993) 0.88
Presence and properties of dihydrofolate reductases within the genus Crithidia. Biochim Biophys Acta (1969) 0.88
Effects of folate deficiency on the metastatic potential of murine melanoma cells. Cancer Res (1988) 0.88
Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol (1995) 0.87
Furanose-pyranose isomerization of reduced pyrimidine and cyclic urea ribosides. J Med Chem (1986) 0.86
Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J Med Chem (1990) 0.86
Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. J Med Chem (1998) 0.86
Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles. Cancer Res (1986) 0.85
Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem Pharmacol (1993) 0.84
Comparative activity and properties of lactate dehydrogenase, xanthine dehydrogenase, and dihydrofolate reductase in normal and Brugia pagangi-infected Aedes aegypti. J Parasitol (1977) 0.83
Cimetidine and the immune response. I. In vivo augmentation of nonspecific and specific immune response. Clin Immunol Immunopathol (1983) 0.82
Dihydrofolate reductase from Trypanosoma equiperdum. II. Inhibition by 2,4-diaminopyrimidines and related heterocycles. J Med Chem (1969) 0.82
Dihydrofolate reductases within the genus Trypanosoma. Exp Parasitol (1969) 0.82
Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice. Cancer Res (1982) 0.82
Drug resistance results in alterations in expression of immune recognition molecules and failure to express Fas (CD95). Immunol Cell Biol (1998) 0.82
Xanthine oxidase-mediated oxidation of epinephrine. Biochem Pharmacol (1971) 0.82
Technical bulletin No. 35. Investigation of the validity of temperature correction factors for serum aspartate and alanine transaminases. Ann Clin Biochem (1975) 0.82
Inhibition of dihydrofolate reductases by derivatives of 2,4-diaminopyrroloquinazoline. Biochem Pharmacol (1979) 0.81
The gel-filtration behaviour of dihydrofolate reductases from culture forms of trypanosomatids. Biochim Biophys Acta (1969) 0.81
B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol (1996) 0.81
Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs. Cancer Res (1985) 0.81
Effect of osmotic diuresis on gentamicin-induced nephrotoxicity in rats. Arch Toxicol (1980) 0.80
Bis-phenanthroline derivatives as suitable scaffolds for effective G-quadruplex recognition. Dalton Trans (2010) 0.80
Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro. Cancer Lett (1986) 0.80
Correlation of altered tyrosine phosphorylation with methotrexate resistance in a cisplatin-resistant subline of L1210 cells. Biochem Pharmacol (1996) 0.79
Oxidation of pteridine derivatives in mice. Biochem Pharmacol (1977) 0.79
Investigations on the mechanisms of methotrexate resistance in a cisplatin-resistant L1210 murine leukemia cell subline. Cancer Chemother Pharmacol (1996) 0.79
Aza and diaza bioisosteric anthracene-9,10-diones as antitumor agents. Acta Biochim Pol (1995) 0.79
Effect of erythrocytes on alveolar macrophage cytostatic activity induced by bleomycin lung damage in rats. Cancer Res (1990) 0.79
Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. Mol Pharmacol (1993) 0.79
Collateral methotrexate resistance in cisplatin-selected murine leukemia cells. Braz J Med Biol Res (1999) 0.78
Impact of the basic amine on the biological activity and intracellular distribution of an aza-anthrapyrazole: BBR 3422. Biochem Pharmacol (2001) 0.78
Specific antibody synthesis in vitro. II. Age-associated thymosin enhancement of antitetanus antibody synthesis. Immunopharmacology (1984) 0.78
A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol (1987) 0.78
Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones. Biochem Pharmacol (1997) 0.78
Amelioration of adriamycin and daunorubicin myocardial toxicity by adenosine. Cancer Res (1981) 0.78
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule. Cancer Res (1988) 0.78
6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J Med Chem (1994) 0.77
Clinical pharmacology and metabolism of trimetrexate. Semin Oncol (1988) 0.77
Specific antibody synthesis in vitro. I. Technical considerations. J Immunol Methods (1984) 0.77
Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells. Biochem Pharmacol (1988) 0.77
Trypanocidal properties of 5'-O-Sulfamoyladenosine, a close structural analog of nucleocidin. Exp Parasitol (1970) 0.77
Experimental tumors and aging: local factors that may account for the observed age advantage in the B16 murine melanoma model. Exp Gerontol (1984) 0.77
Assessment of bleomycin-, tallysomycin-, and polyamine-mediated acute lung toxicity by pulmonary lavage angiotensin-converting enzyme activity. Toxicol Appl Pharmacol (1981) 0.77
Activity of 2,4-diaminoquinazoline compounds against Candida species. Antimicrob Agents Chemother (1979) 0.76
Inhibition of mammalian dihydrofolate reductase by selected 2,4-diaminiquinazolines and related compounds. J Med Chem (1974) 0.76
Dihydrofolate reductase inhibitors as potential drugs. Med Res Rev (1981) 0.76
Modulation of methotrexate resistance by genistein in murine leukemia L1210 cells. Oncol Rep (1998) 0.76
Phosphofructokinase activity in particulate-free extracts of Trypanosoma (Trypanozoon) rhodesiense. Comp Biochem Physiol B (1971) 0.76
Synthesis and antitumor activities of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and related systems. J Med Chem (1986) 0.76
Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles). J Med Chem (1998) 0.76
Increased oxidant resistance of alveolar macrophages isolated from rats repeatedly exposed to cadmium aerosols. Toxicology (1996) 0.76
Shikimic acid complexes of platinum. Preparation, reactivity, and antitumor activity of (R,R-1,2-diaminocyclohexane) bis(shikimato) platinum(II). Evidence for a novel rearrangement involving platinum-carbon bond formation. J Inorg Biochem (1991) 0.76
DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action. Mol Pharmacol (2001) 0.76
Role of reactive nitrogen intermediate production in alveolar macrophage-mediated cytostatic activity induced by bleomycin lung damage in rats. Cancer Res (1990) 0.75
Effect of disulfiram on cyclophosphamide toxicity: a clinical trial. Cancer Treat Rep (1983) 0.75
Presence and properties of dihydrofolate reductases within the genus Trypanosoma. Br J Pharmacol (1968) 0.75
Chronobiologic fluctuation of cyclophosphamide induced urinary bladder damage in mice. Chronobiologia (1984) 0.75
Toxicity of aziridinylbenzoquinone administered Iv to beagle dogs. Cancer Treat Rep (1982) 0.75
The effect of L-3, 4-dehydroproline on the antitumor activity and toxicity of bleomycin. Toxicol Appl Pharmacol (1983) 0.75
Fibrogenic structure-activity study of the bleomycin molecule. Toxicol Appl Pharmacol (1983) 0.75
Effect of trimethoprim, paracetamol and cimetidine on trimetrexate metabolism by rat perfused isolated livers. J Pharm Pharmacol (1987) 0.75
Synthesis and antitumor activity of a series of (aminoethylpyrrolidine) platinum complexes. Cancer Chemother Pharmacol (1989) 0.75
Home care in New York City: providers, payers, and clients. Pap Ser United Hosp Fund N Y (1987) 0.75
Vinblastine pharmacokinetics measured by a sensitive enzyme-linked immunosorbent assay. Cancer Res (1984) 0.75
Reduction of acute adriamycin toxicity in mice treated with adenosine. Eur J Cancer Clin Oncol (1983) 0.75
Local collaboration needed for long-term care insurance. Health Prog (1988) 0.75